NewsRoom Articles - Page 191 of 219

WednesdayNov 25, 2020 11:00 am

Microorganisms Found in Child’s Bed Dust May Boost Their Health

In collaboration with the Gentofte Hospital and the Danish Pediatric Asthma Center, University of Copenhagen researchers from the Department of Biology have discovered a connection between children’s bacteria and the microorganisms that exist in the beds of children in an extensive study. This link implies that the microorganisms may decrease the risk of a child developing autoimmune diseases, allergies and asthma as they grow. While these microorganisms are invisible to the naked eye, they exist in multitudes in a child’s bed, influencing the development of microorganisms in children’s bodies. Ultimately, this impacts how resistant children become to different diseases. To…

WednesdayNov 25, 2020 10:45 am

AzurRx BioPharma Inc. (NASDAQ: AZRX) Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsules If it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its drug candidate MS1819 without significant extra costs or delays Enrollment in this arm of the study could begin as early as December 2020 AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, has submitted a protocol amendment request to the U.S. Food and Drug Administration that would allow it to test immediate…

WednesdayNov 25, 2020 10:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) IND Application for Cancer Drug Berubicin Accepted for Review

CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma Multiforme Company believes it’s on track to start in Q1 2021 a potentially pivotal Phase II Berubicin trial with adult GBM patients who have failed their primary treatment for the disease Separately, a Phase II adult trial and a first-ever Phase I pediatric trial are slated to begin in 2021 in Poland in collaboration with sub-licensee partner, WPD Pharmaceuticals Members of CNS’s management team attended A.G.P.’s Virtual Health Symposium, meeting 1-on-1 with investors CNS Pharmaceuticals (NASDAQ: CNSP), a…

TuesdayNov 24, 2020 11:30 am

Researchers Design Wearable Sensors That Can Detect Employee Fatigue

Scientists have been designing devices that detect a worker’s alertness. The aim of this? To monitor for fatigue. Fatigue in a work setting can cause injuries or accidents and sometimes even loss of lives. Various industrial disasters, such as the Chernobyl nuclear accident, have been linked to worker fatigue. These wearable devices measures the breathing rate of their users as well as their muscle contractions, sweating and heart rate. The research, which was reported in this month’s issue of “IEEE Sensors Journal,” has a team of researchers from Italy explain how the innovative device works, adding that the individuals’ breathing…

TuesdayNov 24, 2020 9:30 am

VistaGen Therapeutics (NASDAQ: VTGN) Seeks to Address Rising Incidence of Mental Health Disorders in United States

VistaGen currently developing three novel drug candidates designed to treat central nervous system disorders Anxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatment Prevalence of depressive disorders in U.S. workplace is estimated to result in economic impact of over $210.5 billion per annum COVID-19 pandemic has further exacerbated these conditions, with number of patients displaying anxiety symptoms rising by 93% YoY between January – September 2020 VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications which go beyond the standard of care…

MondayNov 23, 2020 3:16 pm

Brain Scientific Inc. (BRSF) Has Three-Phase Plan to Improve Access to Neurological Care

BRSF is modernizing brain diagnostics with cost-effective, disposable solutions that help minimize risk of spreading disease AI-assisted analysis allows for processing of relevant data in real time at high speed for early diagnosis, higher rate of successful treatments Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics by employing cutting-edge tech to bridge the widening gap in access to quality care. BRSF is achieving this through cost-effective and disposable substitutes to existing solutions that improve patients’ access to neurological care. Currently, BRSF is in phase two of a three-phase plan for development. Phase one of development occurred in 2018–2019 with the…

MondayNov 23, 2020 11:00 am

Brain Protein May Be the Key to New Cancer Treatments

Scientists have discovered that Netrin-G1, a protein that plays a role in neuron development in the brain, also has a hand in the growth and development of pancreatic cancer. The study results show that this particular protein protects pancreatic cancer cells from a person's immune system while also providing important nutrients. Pancreatic cancer is among the hardest cancers to treat as its tumors grow additional connective tissue in the pancreas. This helps the cancer grow while also providing it with a biochemical and physical protective barrier against an individual's immune system as well as the drugs administered to fight the…

FridayNov 20, 2020 1:00 pm

Researchers May Have Found a New Way to Predict Cancer Susceptibility

A new study by researchers from the University of Birmingham suggests that environmental cancer-causing agents may be used to help understand effects of exposure in addition to helping predict the individuals who may be more susceptible to developing cancer. Every individual has been exposed to low levels of radiation or substances that promote cancer development, commonly known as carcinogens. Benzopyrene, which is a widely used chemical pollutant, is found in barbequed fish and meat, exhaust fumes and wood-burning stoves. The pollutant has BPDE, which is an active ingredient that forms DNA adducts. These are damaged DNA that promote mutations that…

FridayNov 20, 2020 11:00 am

Research Finds That Masks Don’t Affect Lung Function When Exercising

A new study published in the “Annals of the American Thoracic Society” indicates that wearing a face mask does not diminish lung function. The team of Canadian and American researchers that worked on the study discovered that while individuals may experience an increase in shortness of breath when wearing a face mask, there was no factual evidence showing that masks decreased lung function. This applies even when masks are worn during heavy exercise. Face mask prevalence has grown since the onset of the coronavirus pandemic and has been touted as a way to effectively reduce the spread of the virus.…

ThursdayNov 19, 2020 2:13 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Outlines Plans for Advancing Drug It Hopes Will Beat Deadly Brain Cancer

Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease The company plans a complex, multi-armed Phase 2 trial of its candidate Berubicin in hopes that the drug candidate may ultimately gain an expedited pathway to approval and registration from the FDA The trial for combatting Glioblastoma Multiforme is expected to begin next year, and on Nov. 12 the company’s officers launched a webinar to provide information on how the trial will be designed CNS Pharmaceuticals is…